| Literature DB >> 34721424 |
Zachary J Morse1, Marc S Horwitz1.
Abstract
In addition to genetic predisposition, environmental determinants contribute to a complex etiology leading to onset of type 1 diabetes (T1D). Multiple studies have established the gut as an important site for immune modulation that can directly impact development of autoreactive cell populations against pancreatic self-antigens. Significant efforts have been made to unravel how changes in the microbiome function as a contributor to autoimmune responses and can serve as a biomarker for diabetes development. Large-scale longitudinal studies reveal that common environmental exposures precede diabetes pathology. Virus infections, particularly those associated with the gut, have been prominently identified as risk factors for T1D development. Evidence suggests recent-onset T1D patients experience pre-existing subclinical enteropathy and dysbiosis leading up to development of diabetes. The start of these dysbiotic events coincide with detection of virus infections. Thus viral infection may be a contributing driver for microbiome dysbiosis and disruption of intestinal homeostasis prior to T1D onset. Ultimately, understanding the cross-talk between viral infection, the microbiome, and the immune system is key for the development of preventative measures against T1D.Entities:
Keywords: autoimmunity; coxsackievirus; dysbiosis; gut; microbiome; type 1 diabetes
Mesh:
Year: 2021 PMID: 34721424 PMCID: PMC8554326 DOI: 10.3389/fimmu.2021.751337
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
Figure 1Virus infections alter intestinal homeostasis to contribute to T1D. The GI environment is tightly regulated by numerous mechanisms. Perturbations such as virus infection results in dysbiosis and disruption to the enteric environment. Microbial dysbiosis is characterized by loss of species diversity and production of SCFAs including butyrate and acetate. As a result of dysbiosis and inflammation, the epithelial barrier becomes more permeable due to loss of tight junctions between epithelial cells, alteration of secreted IgA (sIgA) antibodies, and diminished mucus production. Some persistent infections may be maintained contributing to sustained inflammatory signalling within the gut. Both pancreatic self-antigens and commensal microbial antigens are taken up by APCs and presented to T cells in the pLN causing loss of self-tolerance. These autoreactive T cells migrate to the pancreas to contribute to anti-islet responses and destruction of insulin-secreting beta cells. Individuals would progress to T1D once sufficient beta cell mass is lost resulting in loss of blood glucose regulation.
Highlighted recent studies depicting intestinal changes associated with T1D.
| Organism | Virus | Result | Microbiome Dysbiosis | Intestinal Pathology | Intestinal Immune Changes | Ref |
|---|---|---|---|---|---|---|
| NOD mice | None | Butyrate and acetate SCFA administration protects from T1D | Increased | SCFA treatment reduced systemic bacterial translocation and increased expression of tight junction proteins | SCFA treatment promotes increased Treg populations, altered B cell differentiation and function, increased serum IL-22, and decreased serum IL-21. | Marino et al. ( |
| NOD Mice | None | NOD mice receiving FMT from T1D patients had modified IgA immunity to GI bacteria. Acetate treatment reverses IgA dysfunction. | Decreased diversity, decreased | NOD mice receiving FMT from T1D donors experience heightened intestinal permeability, increased IgA immunity, and decreased AMP expression | Acetate treatment increases gut-associated Tregs and decreases IgA+ B cells. | Huang et al. ( |
| NOD mice | None | Low-grade DSS administration is able to induce T1D. | DSS treatment alters microbiome, however FMT of dysbiotic DSS-induced microbiome to naïve mice is insufficient to promote T1D alone | Increased permeability triggers T1D (NOD mice have decreased tight junction protein expression, and reduced mucosal barrier | Increased intestinal permeability activates islet-reactive T cells and increased gut related T cell infiltration into the pancreatic islets. | Sorini et al. ( |
| NOD mice | None | Intestinal homeostasis is altered in NOD prior to T1D onset. | Increased | Prediabetic NOD mice have increased intestinal permeability, diminished mucus production, bacterial translocation, and reduced IgA. | Prior to T1D onset, mice have elevated Th1 and Th17 responses as well as decreased Th2 cells, ILC2s, and Tregs in the small intestine. | Miranda et al. ( |
| NOD mice | None | TLR4-defiecient NOD mice have accelerated T1D onset. | T1D was associated with increased | Increased bacterial translocation (Serum LPS levels) | ND | Simon et al. ( |
| NOD mice | None | Offspring of NOD mice treated with Vancomycin had increased autoimmunity and those treated with Neomycin experienced protection. | Both case group mice had less segmented filamentous bacteria. Offspring of neomycin-treated mice had less gram-positive bacteria overall, and more | ND | Neomycin-treated mice had significantly less co-stimulatory molecule expression on APCs, and decreased Th1 and Th17 T cells. | Hu et al. ( |
| NOD mice | MNV | MNV infection protects from T1D development. | Increased alpha-diversity, increased | MNV infection causes altered Tuft cell gene expression. No changes in permeability, tight junction, or AMP expression in infected mice. | Infected mice had increased systemic Tregs, reduced inflammatory T cells and cytokine secretion, altered mucosa-associated B cell populations, and increased macrophage recruitment in pLN | Pearson et al. ( |
| Humans | Unknown | Human T1D patients have decreased acetate levels and increased IgA production. | T1D patients had increased bacterial diversity, with decreased | T1D patients had increased IgA-coated bacteria in their stool. | ND | Huang et al. ( |
| Humans | Enterovirus | Small bowel mucosa from T1D patients have increased prevalence of enterovirus. Children who progress to T1D experience sustained enterovirus infections prior to autoimmunity. | ND | Virus positive and T1D patients had increased mucosal IgA deposits. | Virus positive patients had increased CD3 intra-epithelial leukocytes. T1D patients (without celiac disease) had increased HLA-DR expression. | Oikarinen et al. ( |
| Humans | Unknown | Children with islet autoantibodies and who progress to T1D experience intestinal dysbiosis. | Case subjects had decreased anti-inflammatory Prevotella and Butyricimonas bacteria as well as overall decreased microbial diversity. | Individuals with islet autoantibodies and those who progressed to T1D had increased intestinal permeability and decreased mucus production | Seropositive subjects had decreased IgA (decreased stool IGHA1) | Harbison et al. ( |
| Humans | Enterovirus B and intestinal virome | Children with islet autoantibodies experience sustained enterovirus B shedding. Changes in the virome precede T1D-related autoantibody detection. | Genetic risk for T1D confers altered virome. Increased prevalence of | ND | ND | Vehik et al. ( |
ND, no data.